Genital warts and infection with human immunodeficiency virus in high-risk women in Burkina Faso: A longitudinal study

BMC Infectious Diseases

Volumn 11, Issue , 2011, Pages

  Low, Andrea J ^a   Clayton, Tim ^a   Konate, Issouf ^b   Nagot, Nicolas ^c   Ouedraogo, Abdoulaye ^a   Huet, Charlotte ^b   Didelot Rousseau, Marie Noelle ^c   Segondy, Michel ^c   Van de Perre, Philippe ^c   Mayaud, Philippe ^a,b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b CENTRE MURAZ   (Burkina Faso)

^c UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; VIRUS DNA;

ADOLESCENT; ADULT; ARTICLE; BURKINA FASO; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENITAL ULCER; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN PAPILLOMAVIRUS TYPE 6; INCIDENCE; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PREVALENCE; PROSPECTIVE STUDY; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CYTOLOGY; VAGINITIS; VIRUS DETECTION; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; PHYSIOLOGY; VIROLOGY;

ADOLESCENT; ADULT; BURKINA FASO; CONDYLOMATA ACUMINATA; FEMALE; HIV; HIV INFECTIONS; HUMAN PAPILLOMAVIRUS 6; HUMANS; LONGITUDINAL STUDIES; PREVALENCE; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 78651542516     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-11-20     Document Type: Article

References (30)

1. Burchell AN, Winer RL, de Sanjose S, Franco EL. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006, 24(Suppl 3):S52-61.
2. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998, 338:423-428. 10.1056/NEJM199802123380703, 9459645.
3. Massad LS, Silverberg MJ, Springer G, Minkoff H, Hessol N, Palefsky JM, Strickler HD, Levine AM, Sacks HS, Moxley M, Heather Watts D. Effect of antiretroviral therapy on the incidence of genital warts and vulvar neoplasia among women with the human immunodeficiency virus. Am J Obstet Gynecol 2004, 190:1241-1248. 10.1016/j.ajog.2003.12.037, 15167825.
4. Moscicki AB, Ellenberg JH, Farhat S, Xu J. Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis 2004, 190:37-45. 10.1086/421467, 15195241.
5. Roman A, Fife KH. Human papillomaviruses: are we ready to type?. Clin Microbiol Rev 1989, 2:166-190. 358109, 2539898.
6. Aubin F, Pretet JL, Jacquard AC, Saunier M, Carcopino X, Jaroud F, Pradat P, Soubeyrand B, Leocmach Y, Mougin C, Riethmuller D. Human papillomavirus genotype distribution in external acuminata condylomata: a Large French National Study (EDiTH IV). Clin Infect Dis 2008, 47:610-615. 10.1086/590560, 18637758.
7. Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, Barr E, Haupt RM, Joura EA. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009, 199:805-814. 10.1086/597071, 19199546.
8. Wall SR, Scherf CF, Morison L, Hart KW, West B, Ekpo G, Fiander AN, Man S, Gelder CM, Walraven G, Borysiewicz LK. Cervical human papillomavirus infection and squamous intraepithelial lesions in rural Gambia, West Africa: viral sequence analysis and epidemiology. Br J Cancer 2005, 93:1068-1076. 10.1038/sj.bjc.6602736, 2361674, 16106268.
9. Mayaud P, Gill DK, Weiss HA, Uledi E, Kopwe L, Todd J, ka-Gina G, Grosskurth H, Hayes RJ, Mabey DC, Lacey CJ. The interrelation of HIV, cervical human papillomavirus, and neoplasia among antenatal clinic attenders in Tanzania. Sex Transm Infect 2001, 77:248-254. 10.1136/sti.77.4.248, 1744347, 11463923.
10. Didelot-Rousseau MN, Nagot N, Costes-Martineau V, Valles X, Ouedraogo A, Konate I, Weiss HA, Van de Perre P, Mayaud P, Segondy M. Human papillomavirus genotype distribution and cervical squamous intraepithelial lesions among high-risk women with and without HIV-1 infection in Burkina Faso. Br J Cancer 2006, 95:355-362. 10.1038/sj.bjc.6603252, 2360631, 16832413.
11. Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA. Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 2009, 101:1120-1130. 10.1093/jnci/djp205, 2728745, 19648510.
12. Lacey CJ. Therapy for genital human papillomavirus-related disease. J Clin Virol 2005, 32(Suppl 1):S82-90. 10.1016/j.jcv.2004.10.020, 15753016.
13. Silverberg MJ, Ahdieh L, Munoz A, Anastos K, Burk RD, Cu-Uvin S, Duerr A, Greenblatt RM, Klein RS, Massad S, et al. The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts. Sex Transm Dis 2002, 29:427-435. 10.1097/00007435-200208000-00001, 12172526.
14. Heard I, Tassie JM, Schmitz V, Mandelbrot L, Kazatchkine MD, Orth G. Increased risk of cervical disease among human immunodeficiency virus-infected women with severe immunosuppression and high human papillomavirus load(1). Obstet Gynecol 2000, 96:403-409. 10.1016/S0029-7844(00)00948-0, 10960634.
15. Dolev JC, Maurer T, Springer G, Glesby MJ, Minkoff H, Connell C, Young M, Schowalter K, Cox C, Hessol NA. Incidence and risk factors for verrucae in women. AIDS 2008, 22:1213-1219. 10.1097/QAD.0b013e3283021aa3, 2615554, 18525267.
16. World Health Organization. Dept. of HIV/AIDS. Interim WHO Antiretroviral Treatment Working Group Scaling up antiretroviral therapy in resource-limited settings guidelines for a public health approach 2002, Geneva: World Health Organization, World Health Organization. Dept. of HIV/AIDS. Interim WHO Antiretroviral Treatment Working Group.
17. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 1991, 29:297-301. 269757, 1706728.
18. Nagot N, Ouedraogo A, Ouangre A, Cartoux M, Defer MC, Meda N, Van de Perre P. Is sexually transmitted infection management among sex workers still able to mitigate the spread of HIV infection in West Africa?. J Acquir Immune Defic Syndr 2005, 39:454-458. 10.1097/01.qai.0000152399.54648.b9, 16010169.
19. Rouet F, Chaix ML, Nerrienet E, Ngo-Giang-Huong N, Plantier JC, Burgard M, Peeters M, Damond F, Ekouevi DK, Msellati P, et al. Impact of HIV-1 genetic diversity on plasma HIV-1 RNA Quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test. J Acquir Immune Defic Syndr 2007, 45:380-388. 10.1097/QAI.0b013e3180640cf5, 17468666.
20. Didelot-Rousseau MN, Courgnaud V, Nagot N, Ouedraogo A, Konate I, Mayaud P, Weiss H, Van de Perre P, Segondy M. Comparison of INNO-LiPA HPV Genotyping v2 with PCR product subcloning and sequencing for identification of genital human papillomavirus genotypes in African women. J Virol Methods 2006, 135:181-185. 10.1016/j.jviromet.2006.03.015, 16675035.
21. Smith JH. Bethesda 2001. Cytopathology 2002, 13:4-10. 10.1046/j.1365-2303.2002.00397.x, 11985563.
22. Xue X, Gange SJ, Zhong Y, Burk RD, Minkoff H, Massad LS, Watts DH, Kuniholm MH, Anastos K, Levine AM, et al. Marginal and mixed-effects models in the analysis of human papillomavirus natural history data. Cancer Epidemiol Biomarkers Prev 2010, 19:159-169. 10.1158/1055-9965.EPI-09-0546, 2839537, 20056635.
23. Low A, Didelot-Rousseau MN, Nagot N, Ouedraougo A, Clayton T, Konate I, Van de Perre P, Segondy M, Mayaud P. Cervical infection with human papillomavirus (HPV) 6 or 11 in high-risk women in Burkina Faso. Sex Transm Infect 2010,
24. Mayaud P, Weiss HA, Lacey CJ, Gill DK, Mabey DC. Genital human papillomavirus genotypes in northwestern Tanzania. J Clin Microbiol 2003, 41:4451-4453. 10.1128/JCM.41.9.4451-4453.2003, 193856, 12958291.
25. Hong K, Greer CE, Ketter N, Van Nest G, Paliard X. Isolation and characterization of human papillomavirus type 6-specific T cells infiltrating genital warts. J Virol 1997, 71:6427-6432. 191916, 9261360.
26. Jain S, Moore RA, Anderson DM, Gough GW, Stanley MA. Cell-mediated immune responses to COPV early proteins. Virology 2006, 356:23-34. 10.1016/j.virol.2006.07.032, 16949120.
27. Watts DH, Fazzari M, Minkoff H, Hillier SL, Sha B, Glesby M, Levine AM, Burk R, Palefsky JM, Moxley M, et al. Effects of bacterial vaginosis and other genital infections on the natural history of human papillomavirus infection in HIV-1-infected and high-risk HIV-1-uninfected women. J Infect Dis 2005, 191:1129-1139. 10.1086/427777, 15747249.
28. Huet C, Ouedraogo A, Konate I, Traore I, Rouet F, Ouiminga A, A S, Mayaud P, Van de Perre P, Nagot N. Feasibility and efficacy of highly active antiretroviral therapy among high-risk and marginalised HIV-1 infected women in West Africa. Book Feasibility and efficacy of highly active antiretroviral therapy among high-risk and marginalised HIV-1 infected women in West Africa 2009, City.
29. Minkoff H, Zhong Y, Burk RD, Palefsky JM, Xue X, Watts DH, Levine AM, Wright RL, Colie C, D'Souza G, et al. Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Infect Dis 2010, 201:681-690. 10.1086/650467, 20105077.
30. Vandepapeliere P, Barrasso R, Meijer CJ, Walboomers JM, Wettendorff M, Stanberry LR, Lacey CJ. Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. J Infect Dis 2005, 192:2099-2107. 10.1086/498164, 16288373.